Along with the patient data showing that high expression of these factors is correlated with poor patient prognosis (Figure 1A–1D, and Figure 4E), these results suggest that CD70 or HIF-2α can be promising targets for cancer therapeutics. This evidence concerns the gene CD70 and cancer.